Answer
Erythema multiforme and generalised exfoliative dermatitis have been reported with capivasertib (Truqap), and patients should be monitored for signs and symptoms of rash or dermatitis.
Sources for this answer
- Truqap 160 mg film-coated tabletsAstraZeneca UK Limited · emc · SmPC §4.4 Special warnings and precautions for use · Version 5Document updated
Sources checked